Medical Stocks

Baxter International Inc. Quarterly Valuation – March 2015 $BAX

500px-Baxter.svg

Baxter International Inc. should satisfy the Enterprising Investor, but not the Defensive Investor. The Defensive Investor is concerned with the low current ratio and the high PB ratio. The Enterprising Investor is only concerned by the level of debt relative to the net current assets. Therefore, Enterprising Investors should feel very comfortable proceeding to the next part of the analysis, which is a determination of the company’s intrinsic value.

From a valuation side of things, the company has grown its EPSmg (normalized earnings) from $2.88 in 2010 to $4.01 for 2014. This is a strong level of demonstrated growth, which is in line with the market’s implied estimate for earnings growth of 4.19% over the next 7-10 years. The ModernGraham valuation model, therefore, returns an estimate of intrinsic value falling within a margin of safety relative to the current price, indicating the company is fairly valued at the present time.

Be sure to check out previous ModernGraham valuations of Baxter International Inc. (BAX) for a greater perspective!

Read the full valuation on Seeking Alpha!

BAX Chart

BAX data by YCharts

Disclaimer: The author did not hold a position in Baxter International Inc. (BAX) at the time of publication and had no intention of changing that position within the next 72 hours. Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top